Edwin Liu
Concepts (344)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Celiac Disease | 61 | 2024 | 286 | 10.610 |
Why?
| Autoantibodies | 48 | 2024 | 1466 | 3.210 |
Why?
| Transglutaminases | 27 | 2024 | 153 | 2.940 |
Why?
| HLA-DQ Antigens | 11 | 2019 | 179 | 1.970 |
Why?
| Autoimmune Diseases | 8 | 2019 | 426 | 1.680 |
Why?
| Autoimmunity | 23 | 2024 | 862 | 1.600 |
Why?
| Diet, Gluten-Free | 10 | 2024 | 42 | 1.500 |
Why?
| Diabetes Mellitus, Type 1 | 47 | 2024 | 3628 | 1.450 |
Why?
| Genetic Predisposition to Disease | 21 | 2024 | 2282 | 1.330 |
Why?
| Insulin | 24 | 2009 | 2326 | 1.310 |
Why?
| Peptide Fragments | 15 | 2008 | 692 | 1.280 |
Why?
| GTP-Binding Proteins | 11 | 2024 | 157 | 1.230 |
Why?
| Glutens | 10 | 2023 | 57 | 1.000 |
Why?
| HLA-DR3 Antigen | 3 | 2015 | 80 | 0.930 |
Why?
| Islets of Langerhans | 17 | 2017 | 791 | 0.890 |
Why?
| HLA-DR Antigens | 5 | 2017 | 224 | 0.770 |
Why?
| Insulin Antibodies | 11 | 2013 | 105 | 0.770 |
Why?
| Genetic Testing | 6 | 2015 | 428 | 0.650 |
Why?
| Pyrrolidinones | 1 | 2019 | 29 | 0.640 |
Why?
| Child | 43 | 2024 | 20883 | 0.630 |
Why?
| Child, Preschool | 30 | 2024 | 10517 | 0.600 |
Why?
| Mice, Inbred NOD | 22 | 2013 | 588 | 0.590 |
Why?
| Patient Compliance | 2 | 2023 | 565 | 0.590 |
Why?
| Mass Screening | 8 | 2024 | 1149 | 0.570 |
Why?
| Down Syndrome | 2 | 2023 | 481 | 0.560 |
Why?
| Anticonvulsants | 1 | 2019 | 209 | 0.550 |
Why?
| Diabetes Mellitus, Experimental | 3 | 2006 | 182 | 0.500 |
Why?
| Epilepsy | 1 | 2019 | 329 | 0.470 |
Why?
| Infant | 26 | 2024 | 9024 | 0.460 |
Why?
| Caregivers | 1 | 2022 | 815 | 0.450 |
Why?
| Anaphylaxis | 3 | 2004 | 98 | 0.440 |
Why?
| Humans | 82 | 2024 | 129650 | 0.440 |
Why?
| Depression | 2 | 2022 | 1307 | 0.430 |
Why?
| Poly I-C | 4 | 2008 | 62 | 0.420 |
Why?
| Female | 56 | 2024 | 68776 | 0.400 |
Why?
| Gliadin | 3 | 2018 | 13 | 0.390 |
Why?
| Adolescent | 23 | 2024 | 20393 | 0.380 |
Why?
| Prospective Studies | 21 | 2024 | 7133 | 0.380 |
Why?
| Radioimmunoassay | 3 | 2016 | 175 | 0.370 |
Why?
| Polymorphism, Single Nucleotide | 7 | 2024 | 2073 | 0.370 |
Why?
| Follow-Up Studies | 12 | 2024 | 4897 | 0.370 |
Why?
| Male | 47 | 2024 | 63681 | 0.360 |
Why?
| Jejunum | 1 | 2011 | 30 | 0.360 |
Why?
| Adjuvants, Immunologic | 3 | 2007 | 221 | 0.350 |
Why?
| Clinical Laboratory Techniques | 1 | 2011 | 94 | 0.330 |
Why?
| Sensitivity and Specificity | 9 | 2017 | 1838 | 0.320 |
Why?
| Immunoglobulin A | 8 | 2024 | 200 | 0.320 |
Why?
| Risk Factors | 17 | 2024 | 9765 | 0.310 |
Why?
| Liver Failure, Acute | 2 | 2008 | 64 | 0.310 |
Why?
| Intestinal Mucosa | 3 | 2023 | 590 | 0.300 |
Why?
| Luminescent Measurements | 2 | 2020 | 78 | 0.300 |
Why?
| Dietary Proteins | 2 | 2019 | 129 | 0.290 |
Why?
| Laboratories | 1 | 2009 | 110 | 0.290 |
Why?
| Mice | 32 | 2013 | 16937 | 0.280 |
Why?
| Interferon-alpha | 2 | 2005 | 194 | 0.270 |
Why?
| Wheat Hypersensitivity | 1 | 2007 | 4 | 0.270 |
Why?
| Poly A-U | 1 | 2006 | 4 | 0.270 |
Why?
| Europe | 6 | 2017 | 364 | 0.260 |
Why?
| T-Lymphocytes | 7 | 2008 | 1928 | 0.260 |
Why?
| Immune Tolerance | 4 | 2013 | 355 | 0.260 |
Why?
| Biopsy | 9 | 2023 | 1097 | 0.250 |
Why?
| Serologic Tests | 4 | 2021 | 52 | 0.250 |
Why?
| HLA Antigens | 5 | 2019 | 234 | 0.240 |
Why?
| Quality of Life | 4 | 2024 | 2704 | 0.230 |
Why?
| Celiac Plexus | 1 | 2024 | 2 | 0.230 |
Why?
| Dyspepsia | 1 | 2024 | 10 | 0.230 |
Why?
| CD4 Antigens | 2 | 2003 | 138 | 0.220 |
Why?
| Antibodies | 3 | 2014 | 398 | 0.220 |
Why?
| Enzyme-Linked Immunosorbent Assay | 6 | 2010 | 833 | 0.220 |
Why?
| Time Factors | 9 | 2017 | 6556 | 0.220 |
Why?
| Animals | 34 | 2015 | 35361 | 0.220 |
Why?
| Electrochemical Techniques | 2 | 2021 | 48 | 0.220 |
Why?
| Peptides | 3 | 2018 | 925 | 0.210 |
Why?
| Genotype | 7 | 2019 | 1839 | 0.210 |
Why?
| Autoantigens | 6 | 2009 | 417 | 0.210 |
Why?
| Diet | 4 | 2019 | 1213 | 0.210 |
Why?
| Abdominal Pain | 1 | 2024 | 144 | 0.210 |
Why?
| Endosonography | 1 | 2024 | 143 | 0.210 |
Why?
| Mice, Inbred BALB C | 8 | 2009 | 1245 | 0.200 |
Why?
| Seasons | 1 | 2024 | 502 | 0.190 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2006 | 704 | 0.190 |
Why?
| Ileal Diseases | 1 | 2001 | 13 | 0.190 |
Why?
| Predictive Value of Tests | 7 | 2015 | 1952 | 0.190 |
Why?
| Short Bowel Syndrome | 1 | 2001 | 26 | 0.190 |
Why?
| Catheterization | 2 | 2001 | 175 | 0.190 |
Why?
| Colonic Diseases | 1 | 2001 | 32 | 0.190 |
Why?
| Proportional Hazards Models | 7 | 2019 | 1201 | 0.180 |
Why?
| Mice, Transgenic | 7 | 2013 | 2119 | 0.180 |
Why?
| Biomarkers | 6 | 2023 | 3973 | 0.170 |
Why?
| Environmental Exposure | 1 | 2024 | 462 | 0.170 |
Why?
| CD4-Positive T-Lymphocytes | 7 | 2008 | 1056 | 0.170 |
Why?
| Delayed Diagnosis | 1 | 2020 | 79 | 0.170 |
Why?
| Infant, Newborn | 8 | 2019 | 5762 | 0.170 |
Why?
| Psychiatric Status Rating Scales | 1 | 2022 | 529 | 0.170 |
Why?
| Incidence | 5 | 2022 | 2644 | 0.160 |
Why?
| Vaccines | 1 | 2004 | 398 | 0.160 |
Why?
| Enterovirus | 1 | 2019 | 78 | 0.150 |
Why?
| Probiotics | 1 | 2019 | 51 | 0.150 |
Why?
| Prevalence | 3 | 2023 | 2564 | 0.150 |
Why?
| Diabetes Mellitus | 2 | 2007 | 1001 | 0.150 |
Why?
| Duodenum | 3 | 2023 | 75 | 0.150 |
Why?
| Risk | 3 | 2019 | 854 | 0.150 |
Why?
| Immunization | 4 | 2007 | 411 | 0.150 |
Why?
| Risk Assessment | 8 | 2020 | 3240 | 0.150 |
Why?
| Nutritionists | 1 | 2018 | 16 | 0.150 |
Why?
| Antibodies, Monoclonal | 2 | 2009 | 1367 | 0.150 |
Why?
| Inflammatory Bowel Diseases | 1 | 2022 | 320 | 0.150 |
Why?
| Adoptive Transfer | 4 | 2008 | 218 | 0.140 |
Why?
| Anxiety | 2 | 2022 | 966 | 0.140 |
Why?
| Parents | 2 | 2024 | 1309 | 0.130 |
Why?
| Feces | 1 | 2019 | 440 | 0.130 |
Why?
| Thyroiditis, Autoimmune | 1 | 2016 | 15 | 0.130 |
Why?
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 2 | 2013 | 45 | 0.130 |
Why?
| Cesarean Section | 1 | 2018 | 182 | 0.130 |
Why?
| Cross-Sectional Studies | 3 | 2023 | 5066 | 0.130 |
Why?
| Surveys and Questionnaires | 3 | 2024 | 5406 | 0.130 |
Why?
| Anorexia Nervosa | 1 | 2017 | 84 | 0.130 |
Why?
| Epitopes, T-Lymphocyte | 2 | 2007 | 186 | 0.130 |
Why?
| Gastroenteritis | 1 | 2016 | 67 | 0.120 |
Why?
| Disease Models, Animal | 5 | 2006 | 4063 | 0.120 |
Why?
| United States | 8 | 2023 | 13903 | 0.120 |
Why?
| HLA-DP beta-Chains | 1 | 2015 | 84 | 0.120 |
Why?
| HLA-DR4 Antigen | 1 | 2014 | 78 | 0.110 |
Why?
| Case-Control Studies | 6 | 2019 | 3381 | 0.110 |
Why?
| Immunoglobulin G | 3 | 2021 | 847 | 0.110 |
Why?
| Weight Gain | 1 | 2017 | 510 | 0.110 |
Why?
| Homozygote | 1 | 2014 | 193 | 0.110 |
Why?
| ROC Curve | 3 | 2013 | 503 | 0.110 |
Why?
| Adaptor Proteins, Signal Transducing | 2 | 2013 | 399 | 0.110 |
Why?
| Mice, Knockout | 8 | 2009 | 2871 | 0.110 |
Why?
| International Cooperation | 2 | 2016 | 174 | 0.100 |
Why?
| Child Development | 1 | 2017 | 457 | 0.100 |
Why?
| Young Adult | 5 | 2024 | 12426 | 0.100 |
Why?
| Clonal Anergy | 1 | 2013 | 51 | 0.100 |
Why?
| Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2012 | 11 | 0.100 |
Why?
| Mice, SCID | 4 | 2008 | 351 | 0.100 |
Why?
| Antigen-Presenting Cells | 1 | 2013 | 150 | 0.100 |
Why?
| B-Lymphocyte Subsets | 1 | 2013 | 74 | 0.100 |
Why?
| Amino Acid Sequence | 3 | 2008 | 2058 | 0.100 |
Why?
| Receptors, Calcitriol | 1 | 2012 | 54 | 0.100 |
Why?
| Protein Precursors | 2 | 2003 | 127 | 0.100 |
Why?
| Sweden | 3 | 2017 | 93 | 0.100 |
Why?
| Retrospective Studies | 5 | 2023 | 14518 | 0.100 |
Why?
| Kaplan-Meier Estimate | 1 | 2014 | 857 | 0.100 |
Why?
| Treatment Outcome | 4 | 2024 | 10230 | 0.090 |
Why?
| Colorado | 2 | 2024 | 4421 | 0.090 |
Why?
| Breast Feeding | 1 | 2015 | 424 | 0.090 |
Why?
| Bone Density | 1 | 2015 | 471 | 0.090 |
Why?
| Heterozygote | 2 | 2016 | 272 | 0.090 |
Why?
| Adenoviridae | 2 | 2019 | 192 | 0.090 |
Why?
| Anti-Bacterial Agents | 2 | 2018 | 1717 | 0.090 |
Why?
| Proinsulin | 3 | 2008 | 52 | 0.090 |
Why?
| Plant Proteins | 1 | 2011 | 89 | 0.090 |
Why?
| Mice, Inbred C57BL | 8 | 2013 | 5440 | 0.080 |
Why?
| Immunoglobulin E | 2 | 2021 | 329 | 0.080 |
Why?
| Feeding Behavior | 1 | 2015 | 624 | 0.080 |
Why?
| Reproducibility of Results | 3 | 2024 | 3083 | 0.080 |
Why?
| CD8-Positive T-Lymphocytes | 2 | 2006 | 857 | 0.080 |
Why?
| Monitoring, Immunologic | 1 | 2009 | 23 | 0.080 |
Why?
| Prothrombin Time | 2 | 2008 | 33 | 0.080 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 1279 | 0.080 |
Why?
| Decision Support Techniques | 1 | 2013 | 396 | 0.080 |
Why?
| Radioligand Assay | 1 | 2009 | 48 | 0.080 |
Why?
| Bilirubin | 2 | 2008 | 96 | 0.080 |
Why?
| Prediabetic State | 3 | 2009 | 246 | 0.080 |
Why?
| Ammonia | 2 | 2008 | 62 | 0.080 |
Why?
| Intracellular Fluid | 1 | 2008 | 27 | 0.080 |
Why?
| Vaccines, DNA | 1 | 2008 | 28 | 0.080 |
Why?
| Severity of Illness Index | 2 | 2008 | 2742 | 0.080 |
Why?
| Injections, Subcutaneous | 3 | 2004 | 147 | 0.080 |
Why?
| Genes, T-Cell Receptor alpha | 1 | 2008 | 12 | 0.080 |
Why?
| Spleen | 3 | 2007 | 507 | 0.070 |
Why?
| Hyperglycemia | 2 | 2008 | 328 | 0.070 |
Why?
| Biopsy, Needle | 2 | 2011 | 189 | 0.070 |
Why?
| Disease Progression | 6 | 2016 | 2635 | 0.070 |
Why?
| Cohort Studies | 5 | 2017 | 5420 | 0.070 |
Why?
| Cholera Toxin | 1 | 2007 | 31 | 0.070 |
Why?
| B7-1 Antigen | 2 | 2004 | 61 | 0.070 |
Why?
| Adult | 8 | 2023 | 35576 | 0.070 |
Why?
| Histocompatibility Antigens | 1 | 2008 | 107 | 0.070 |
Why?
| Forkhead Transcription Factors | 1 | 2008 | 185 | 0.070 |
Why?
| Self-Help Groups | 1 | 2007 | 34 | 0.070 |
Why?
| Blood Glucose | 3 | 2006 | 2097 | 0.070 |
Why?
| Disease Susceptibility | 2 | 2020 | 333 | 0.070 |
Why?
| Genes, RAG-1 | 1 | 2006 | 12 | 0.070 |
Why?
| Interferon-gamma | 2 | 2008 | 770 | 0.070 |
Why?
| Crosses, Genetic | 1 | 2006 | 142 | 0.060 |
Why?
| Mice, Mutant Strains | 1 | 2006 | 298 | 0.060 |
Why?
| Antibody Formation | 1 | 2007 | 290 | 0.060 |
Why?
| Logistic Models | 3 | 2017 | 1988 | 0.060 |
Why?
| Education, Continuing | 1 | 2006 | 39 | 0.060 |
Why?
| Pediatrics | 2 | 2016 | 1052 | 0.060 |
Why?
| Intestine, Small | 1 | 2007 | 150 | 0.060 |
Why?
| Dose-Response Relationship, Drug | 2 | 2017 | 2012 | 0.060 |
Why?
| Age Factors | 3 | 2017 | 3144 | 0.060 |
Why?
| Isoelectric Point | 1 | 2004 | 23 | 0.060 |
Why?
| Autonomic Nerve Block | 1 | 2024 | 4 | 0.060 |
Why?
| Antibodies, Heterophile | 1 | 2004 | 14 | 0.060 |
Why?
| CD3 Complex | 1 | 2024 | 103 | 0.060 |
Why?
| Survival Rate | 2 | 2007 | 1877 | 0.060 |
Why?
| B-Lymphocytes | 1 | 2009 | 815 | 0.050 |
Why?
| Molecular Sequence Data | 2 | 2008 | 2832 | 0.050 |
Why?
| Pancreatitis, Chronic | 1 | 2024 | 51 | 0.050 |
Why?
| Immunity, Mucosal | 1 | 2004 | 94 | 0.050 |
Why?
| Nerve Block | 1 | 2024 | 65 | 0.050 |
Why?
| Ultrasonography, Interventional | 1 | 2024 | 128 | 0.050 |
Why?
| Neonatal Screening | 1 | 2005 | 163 | 0.050 |
Why?
| Cyclophosphamide | 1 | 2003 | 232 | 0.050 |
Why?
| Gene-Environment Interaction | 1 | 2024 | 185 | 0.050 |
Why?
| Genetic Markers | 2 | 2015 | 338 | 0.050 |
Why?
| Hydrogen-Ion Concentration | 1 | 2004 | 544 | 0.050 |
Why?
| Epitopes | 1 | 2005 | 470 | 0.050 |
Why?
| Enkephalins | 1 | 2002 | 16 | 0.050 |
Why?
| Pyridinium Compounds | 1 | 2002 | 25 | 0.050 |
Why?
| Anemia, Pernicious | 1 | 2002 | 9 | 0.050 |
Why?
| Diagnosis, Differential | 1 | 2007 | 1434 | 0.050 |
Why?
| Polyendocrinopathies, Autoimmune | 1 | 2002 | 18 | 0.050 |
Why?
| Immunotherapy | 1 | 2007 | 592 | 0.050 |
Why?
| Gene Expression Regulation | 2 | 2008 | 2548 | 0.050 |
Why?
| Animals, Newborn | 1 | 2004 | 835 | 0.050 |
Why?
| Thyroid Diseases | 1 | 2002 | 35 | 0.050 |
Why?
| Addison Disease | 1 | 2002 | 43 | 0.050 |
Why?
| Histocompatibility Antigens Class II | 1 | 2003 | 362 | 0.050 |
Why?
| Immunologic Deficiency Syndromes | 1 | 2002 | 63 | 0.050 |
Why?
| Oligopeptides | 1 | 2003 | 257 | 0.050 |
Why?
| Paracentesis | 1 | 2001 | 12 | 0.050 |
Why?
| Gastroschisis | 1 | 2001 | 21 | 0.050 |
Why?
| Ascites | 1 | 2001 | 44 | 0.050 |
Why?
| Diagnostic Techniques, Radioisotope | 1 | 2021 | 9 | 0.050 |
Why?
| Immunoglobulin D | 1 | 2021 | 29 | 0.040 |
Why?
| Anastomosis, Surgical | 1 | 2001 | 149 | 0.040 |
Why?
| Patient Reported Outcome Measures | 1 | 2024 | 373 | 0.040 |
Why?
| Prognosis | 2 | 2008 | 3794 | 0.040 |
Why?
| Psychometrics | 1 | 2024 | 691 | 0.040 |
Why?
| Survival Analysis | 1 | 2003 | 1274 | 0.040 |
Why?
| Asymptomatic Diseases | 1 | 2021 | 84 | 0.040 |
Why?
| Gene Expression | 1 | 2005 | 1472 | 0.040 |
Why?
| Self Report | 1 | 2024 | 799 | 0.040 |
Why?
| Algorithms | 1 | 2008 | 1622 | 0.040 |
Why?
| Immunoglobulin M | 1 | 2021 | 275 | 0.040 |
Why?
| Diet Records | 1 | 2019 | 80 | 0.040 |
Why?
| Pilot Projects | 1 | 2024 | 1587 | 0.040 |
Why?
| Liver Cirrhosis | 1 | 2001 | 280 | 0.040 |
Why?
| Colonoscopy | 1 | 2001 | 236 | 0.040 |
Why?
| Practice Guidelines as Topic | 1 | 2007 | 1501 | 0.040 |
Why?
| Infant Formula | 1 | 2019 | 74 | 0.040 |
Why?
| Longitudinal Studies | 2 | 2017 | 2717 | 0.040 |
Why?
| Rats | 2 | 2004 | 5500 | 0.040 |
Why?
| Metagenomics | 1 | 2019 | 156 | 0.040 |
Why?
| Histocompatibility Testing | 1 | 2017 | 120 | 0.040 |
Why?
| Population Surveillance | 1 | 2020 | 439 | 0.040 |
Why?
| Behavior Therapy | 1 | 2020 | 241 | 0.040 |
Why?
| Rotavirus | 1 | 2016 | 20 | 0.030 |
Why?
| Drug Utilization | 1 | 2017 | 171 | 0.030 |
Why?
| Randomized Controlled Trials as Topic | 2 | 2015 | 1368 | 0.030 |
Why?
| Disease Management | 1 | 2020 | 589 | 0.030 |
Why?
| Multiple Sclerosis | 1 | 2002 | 436 | 0.030 |
Why?
| Rotavirus Vaccines | 1 | 2016 | 49 | 0.030 |
Why?
| Reference Values | 2 | 2011 | 793 | 0.030 |
Why?
| Phenotype | 3 | 2015 | 3076 | 0.030 |
Why?
| China | 1 | 2016 | 191 | 0.030 |
Why?
| Ambulatory Care Facilities | 1 | 2017 | 228 | 0.030 |
Why?
| Drug Administration Schedule | 1 | 2017 | 769 | 0.030 |
Why?
| Transcription Factors | 1 | 2003 | 1651 | 0.030 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 2020 | 573 | 0.030 |
Why?
| Aging | 1 | 2005 | 1776 | 0.030 |
Why?
| Dietary Supplements | 1 | 2019 | 534 | 0.030 |
Why?
| DNA Primers | 2 | 2008 | 510 | 0.030 |
Why?
| Vaccination | 1 | 2003 | 1348 | 0.030 |
Why?
| Aggression | 1 | 2017 | 196 | 0.030 |
Why?
| Observational Studies as Topic | 1 | 2015 | 110 | 0.030 |
Why?
| Protective Factors | 1 | 2015 | 91 | 0.030 |
Why?
| Family Health | 1 | 2016 | 198 | 0.030 |
Why?
| Cross-Cultural Comparison | 1 | 2015 | 82 | 0.030 |
Why?
| Gene Frequency | 1 | 2015 | 503 | 0.030 |
Why?
| Sleep Wake Disorders | 1 | 2017 | 252 | 0.030 |
Why?
| Immunohistochemistry | 2 | 2011 | 1698 | 0.030 |
Why?
| Comorbidity | 1 | 2017 | 1547 | 0.030 |
Why?
| Socioeconomic Factors | 1 | 2017 | 1214 | 0.020 |
Why?
| Intestines | 1 | 2015 | 348 | 0.020 |
Why?
| Base Sequence | 2 | 2008 | 2142 | 0.020 |
Why?
| Administration, Oral | 2 | 2004 | 786 | 0.020 |
Why?
| Receptors, Antigen, B-Cell | 1 | 2013 | 126 | 0.020 |
Why?
| Respiratory Tract Infections | 1 | 2016 | 376 | 0.020 |
Why?
| Coculture Techniques | 1 | 2013 | 226 | 0.020 |
Why?
| Evidence-Based Medicine | 1 | 2016 | 718 | 0.020 |
Why?
| Body Mass Index | 1 | 2020 | 2273 | 0.020 |
Why?
| Glutamate Decarboxylase | 1 | 2012 | 166 | 0.020 |
Why?
| Sex Factors | 1 | 2017 | 1968 | 0.020 |
Why?
| Species Specificity | 2 | 2004 | 575 | 0.020 |
Why?
| Mothers | 1 | 2017 | 729 | 0.020 |
Why?
| T-Lymphocyte Subsets | 1 | 2013 | 412 | 0.020 |
Why?
| Models, Genetic | 1 | 2013 | 594 | 0.020 |
Why?
| Pregnancy | 2 | 2018 | 6402 | 0.020 |
Why?
| False Negative Reactions | 1 | 2010 | 53 | 0.020 |
Why?
| Postoperative Complications | 1 | 2001 | 2483 | 0.020 |
Why?
| Age Distribution | 1 | 2011 | 372 | 0.020 |
Why?
| Sex Distribution | 1 | 2011 | 359 | 0.020 |
Why?
| Radioimmunoprecipitation Assay | 1 | 2009 | 6 | 0.020 |
Why?
| Staphylococcal Protein A | 1 | 2009 | 11 | 0.020 |
Why?
| Microchemistry | 1 | 2009 | 20 | 0.020 |
Why?
| Registries | 1 | 2017 | 1896 | 0.020 |
Why?
| Antigens, CD20 | 1 | 2009 | 27 | 0.020 |
Why?
| Sialic Acid Binding Ig-like Lectin 2 | 1 | 2009 | 12 | 0.020 |
Why?
| Europium | 1 | 2009 | 2 | 0.020 |
Why?
| Biotinylation | 1 | 2009 | 29 | 0.020 |
Why?
| Streptavidin | 1 | 2009 | 14 | 0.020 |
Why?
| Dose-Response Relationship, Immunologic | 1 | 2008 | 82 | 0.020 |
Why?
| Lymphocyte Activation | 1 | 2013 | 1106 | 0.020 |
Why?
| Genes, T-Cell Receptor beta | 1 | 2008 | 21 | 0.020 |
Why?
| Clone Cells | 1 | 2008 | 261 | 0.020 |
Why?
| Conserved Sequence | 1 | 2008 | 227 | 0.020 |
Why?
| Plasmids | 1 | 2008 | 358 | 0.020 |
Why?
| Cross-Priming | 1 | 2007 | 18 | 0.020 |
Why?
| Cell Transplantation | 1 | 2007 | 37 | 0.020 |
Why?
| Administration, Intranasal | 1 | 2007 | 84 | 0.020 |
Why?
| Metabolic Networks and Pathways | 1 | 2008 | 178 | 0.020 |
Why?
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2008 | 336 | 0.020 |
Why?
| Bone Marrow Transplantation | 1 | 2007 | 274 | 0.020 |
Why?
| Cells, Cultured | 1 | 2013 | 4083 | 0.010 |
Why?
| Integrin alpha Chains | 1 | 2004 | 23 | 0.010 |
Why?
| Polyethylene Glycols | 1 | 2009 | 601 | 0.010 |
Why?
| Environmental Health | 1 | 2004 | 37 | 0.010 |
Why?
| Maternal-Fetal Exchange | 1 | 2004 | 161 | 0.010 |
Why?
| T-Box Domain Proteins | 1 | 2003 | 96 | 0.010 |
Why?
| Cell Line | 1 | 2008 | 2781 | 0.010 |
Why?
| Age of Onset | 1 | 2004 | 496 | 0.010 |
Why?
| Islets of Langerhans Transplantation | 1 | 2003 | 63 | 0.010 |
Why?
| CD8 Antigens | 1 | 2002 | 76 | 0.010 |
Why?
| Antigens, CD | 1 | 2004 | 489 | 0.010 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2016 | 2441 | 0.010 |
Why?
| Plasma Volume | 1 | 2001 | 19 | 0.010 |
Why?
| Chronic Disease | 1 | 2008 | 1720 | 0.010 |
Why?
| Punctures | 1 | 2001 | 40 | 0.010 |
Why?
| Glucagon | 1 | 2002 | 105 | 0.010 |
Why?
| Major Histocompatibility Complex | 1 | 2002 | 230 | 0.010 |
Why?
| Needles | 1 | 2001 | 57 | 0.010 |
Why?
| Drainage | 1 | 2001 | 165 | 0.010 |
Why?
| Safety | 1 | 2001 | 331 | 0.010 |
Why?
| Alleles | 1 | 2002 | 845 | 0.010 |
Why?
| Immunity, Innate | 1 | 2004 | 804 | 0.010 |
Why?
| Middle Aged | 1 | 2016 | 31154 | 0.010 |
Why?
| Obesity | 1 | 2008 | 2883 | 0.010 |
Why?
| Mutation | 1 | 2003 | 3717 | 0.010 |
Why?
|
|
Liu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|